DelveInsight’s Tuberous Sclerosis Complex Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects across the Tuberous Sclerosis Complex market. The disease summary and Tuberous Sclerosis Complex therapy guidelines are also included in a complete description of the Tuberous Sclerosis Complex pipeline environment.
Some Important Findings from the Tuberous Sclerosis Complex Pipeline Report
Pipeline therapy for Tuberous Sclerosis Complex such as Pascomer is in the Phase II/III of clinical trials.
Some pipeline therapies for Tuberous Sclerosis Complex including Ganaxolone, TAVT-18, and Basimglurant are in the Phase II of clinical trials.
Key companies such as AFT Pharmaceuticals, Marinus Pharmaceuticals, Tavanta Therapeutics, Noema Pharma, among others are actively working towards the development of novel therapies for Tuberous Sclerosis Complex.
To learn more, request sample @ Tuberous Sclerosis Complex Pipeline Assessment
Tuberous Sclerosis Complex: Overview
Tuberous Sclerosis Complex is a hereditary condition that causes the creation of many non-cancerous (benign) tumors throughout the body. These tumors can develop in the skin, brain, kidneys, and other organs. Every day, at least two children are born with Tuberous Sclerosis Complex globally.
Tuberous Sclerosis Complex: Symptoms
Tuberous Sclerosis is a disorder with a wide range of symptoms. Even within the same family, the signs, symptoms, and severity of the condition can differ considerably from one person to the next. Any organ system of the body can be affected.
Tuberous Sclerosis Complex: Treatment
Treatment may necessitate the collaborative efforts of a team of specialists. Pediatricians and general internists, neurologists, dermatologists, cardiologists, dental specialists, eye specialists, psychiatrists, and other healthcare professionals may be required to plan an affected child’s treatment systematically and comprehensively. Affected individuals and their families will benefit from genetic counselling.
Tuberous Sclerosis Complex Pipeline Analysis: Drug Profile
Ganaxolone: Marinus Pharmaceuticals
Product Description
Ganaxolone is a GABAA receptor modulator that influences brain activity. This process can include suppressing abnormal electrical discharges that cause seizures and status epilepticus, as well as restoring balance in disrupted neuronal activity in other CNS disorders.
Research and Development in the Tuberous Sclerosis Complex Pipeline Landscape
Phase II
NCT04285346: In April 2020, Marinus Pharmaceuticals began a Phase 2 open-label 12-week trial of adjunctive ganaxolone treatment (Part A) in Tuberous Sclerosis Complex-related epilepsy followed by long-term treatment (Part B) in Tuberous Sclerosis Complex-related epilepsy. This is an OL proof of concept research of supplemental GNX medication in patients with TSC and/or a mutation in either the TSC1 or TSC2 gene.
Tuberous Sclerosis Complex Pipeline Therapies and Key Companies
Pascomer: AFT Pharmaceuticals
TAVT-18: Tavanta Therapeutics
Basimglurant: Noema Pharma
Get more insights @ Tuberous Sclerosis Complex Pipeline Therapies
Tuberous Sclerosis Complex Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase III
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Scope of the Report
Coverage: Global
Tuberous Sclerosis Complex Key Players: AFT Pharmaceuticals, Marinus Pharmaceuticals, Tavanta Therapeutics, Noema Pharma, among others
Tuberous Sclerosis Complex Pipeline Therapies: Pascomer, Ganaxolone, TAVT-18, Basimglurant, and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
4.
Tuberous Sclerosis Complex- Analytical Perspective In-depth Commercial Assessment
5.
Tuberous Sclerosis Complex Pipeline Therapeutics
6.
Tuberous Sclerosis Complex Late Stage Products (Phase II/III)
7.
Tuberous Sclerosis Complex Mid Stage Products (Phase II)
8.
Tuberous Sclerosis Complex Early Stage Products (Phase I)
9.
Tuberous Sclerosis Complex Preclinical Stage Products
10.
Tuberous Sclerosis Complex Therapeutic Assessment
11.
Tuberous Sclerosis Complex Inactive Products
12.
Tuberous Sclerosis Complex Company-University Collaborations (Licensing/Partnering) Analysis
13.
Tuberous Sclerosis Complex Key Companies
14.
Tuberous Sclerosis Complex Key Products
15.
Tuberous Sclerosis Complex- Unmet Needs
16.
Tuberous Sclerosis Complex- Market Drivers and Barriers
17.
Tuberous Sclerosis Complex- Future Perspectives and Conclusion
18.
Tuberous Sclerosis Complex Analyst Views
19.
Appendix
20.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key questions answered in the Tuberous Sclerosis Complex Pipeline Report
What are the different types of Tuberous Sclerosis Complex treatments?
How many firms are developing medicines for Tuberous Sclerosis Complex?
Which of these firms’ pharmaceuticals is the most popular?
In total, how many Tuberous Sclerosis Complex drugs has each firm produced?
How many novel therapies for Tuberous Sclerosis Complex are in the early, mid, and late stages of development?
How many of the medications in development can be used on their own or in conjunction with other therapies?
What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licensure practises that will have an impact on Tuberous Sclerosis Complex?
Related Reports
Central Precocious Puberty Pipeline Insights
Get comprehensive analysis of Central Precocious Puberty pipeline therapies and key companies including AstraZeneca, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/